Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) - Trial NCT06322108
Access comprehensive clinical trial information for NCT06322108 through Pure Global AI's free database. This Phase 2 trial is sponsored by Immune Oncology Research Institute and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Immune Oncology Research Institute
Timeline & Enrollment
Phase 2
May 01, 2024
Apr 01, 2030
Primary Outcome
12-Month Progression-Free Survival (PFS)
Summary
The goal of this study is to see if the combination of immunotherapy agents botensilimab and
 balstilimab is safe and effective in participants with metastatic non-small cell lung cancer
 (NSCLC) as a first-line treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06322108
Non-Device Trial